PortalPublikationenResponse to First-Line Treatment with Immune-Checkpoint Inhi...

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

Standard

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. / Haist, Maximilian; Stege, Henner; Lang, Berenice Mareen; Tsochataridou, Aikaterini; Salzmann, Martin; Mohr, Peter; Schadendorf, Dirk; Ugurel, Selma; Placke, Jan-Malte; Weichenthal, Michael; Gutzmer, Ralf; Leiter, Ulrike; Kaatz, Martin; Haferkamp, Sebastian; Berking, Carola; Heppt, Markus; Tschechne, Barbara; Schummer, Patrick; Gebhardt, Christoffer; Grabbe, Stephan; Loquai, Carmen.

in: CANCERS, Jahrgang 14, Nr. 22, 5543, 11.11.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Haist, M, Stege, H, Lang, BM, Tsochataridou, A, Salzmann, M, Mohr, P, Schadendorf, D, Ugurel, S, Placke, J-M, Weichenthal, M, Gutzmer, R, Leiter, U, Kaatz, M, Haferkamp, S, Berking, C, Heppt, M, Tschechne, B, Schummer, P, Gebhardt, C, Grabbe, S & Loquai, C 2022, 'Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry', CANCERS, Jg. 14, Nr. 22, 5543. https://doi.org/10.3390/cancers14225543

APA

Haist, M., Stege, H., Lang, B. M., Tsochataridou, A., Salzmann, M., Mohr, P., Schadendorf, D., Ugurel, S., Placke, J-M., Weichenthal, M., Gutzmer, R., Leiter, U., Kaatz, M., Haferkamp, S., Berking, C., Heppt, M., Tschechne, B., Schummer, P., Gebhardt, C., ... Loquai, C. (2022). Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. CANCERS, 14(22), [5543]. https://doi.org/10.3390/cancers14225543

Vancouver

Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P et al. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. CANCERS. 2022 Nov 11;14(22). 5543. https://doi.org/10.3390/cancers14225543

Bibtex

@article{47f92b0a631345288913fcf0e7f2e1a1,
title = "Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry",
abstract = "Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. Among 39 evaluable patients, the tumor response rate (rwTRR) was 48.6%, the median PFS was 29.0 months, and the median OS was not reached. In addition, 9 patients showed an impaired immune status due to immunosuppressive medication or hematological diseases. Our data demonstrated that CPI also evoked tumor responses among immunocompromised patients (rwTRR: 48.1 vs. 50.0%), although these responses less often resulted in durable remissions. In line with this, the median PFS (11 vs. 40 months, p = 0.059), TTNT (12 months vs. NR, p = 0.016), and OS (29 months vs. NR, p < 0.001) were significantly shorter for this patient cohort. CPI therapy was well tolerated in both subcohorts with 15% discontinuing therapy due to toxicity. Our real-world data show that first-line CPI therapy produced strong and durable responses among patients with advanced cSCC. Immunocompromised patients were less likely to achieve long-term benefit from anti-PD1 treatment, despite similar tumor response rates.",
author = "Maximilian Haist and Henner Stege and Lang, {Berenice Mareen} and Aikaterini Tsochataridou and Martin Salzmann and Peter Mohr and Dirk Schadendorf and Selma Ugurel and Jan-Malte Placke and Michael Weichenthal and Ralf Gutzmer and Ulrike Leiter and Martin Kaatz and Sebastian Haferkamp and Carola Berking and Markus Heppt and Barbara Tschechne and Patrick Schummer and Christoffer Gebhardt and Stephan Grabbe and Carmen Loquai",
year = "2022",
month = nov,
day = "11",
doi = "10.3390/cancers14225543",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "22",

}

RIS

TY - JOUR

T1 - Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

AU - Haist, Maximilian

AU - Stege, Henner

AU - Lang, Berenice Mareen

AU - Tsochataridou, Aikaterini

AU - Salzmann, Martin

AU - Mohr, Peter

AU - Schadendorf, Dirk

AU - Ugurel, Selma

AU - Placke, Jan-Malte

AU - Weichenthal, Michael

AU - Gutzmer, Ralf

AU - Leiter, Ulrike

AU - Kaatz, Martin

AU - Haferkamp, Sebastian

AU - Berking, Carola

AU - Heppt, Markus

AU - Tschechne, Barbara

AU - Schummer, Patrick

AU - Gebhardt, Christoffer

AU - Grabbe, Stephan

AU - Loquai, Carmen

PY - 2022/11/11

Y1 - 2022/11/11

N2 - Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. Among 39 evaluable patients, the tumor response rate (rwTRR) was 48.6%, the median PFS was 29.0 months, and the median OS was not reached. In addition, 9 patients showed an impaired immune status due to immunosuppressive medication or hematological diseases. Our data demonstrated that CPI also evoked tumor responses among immunocompromised patients (rwTRR: 48.1 vs. 50.0%), although these responses less often resulted in durable remissions. In line with this, the median PFS (11 vs. 40 months, p = 0.059), TTNT (12 months vs. NR, p = 0.016), and OS (29 months vs. NR, p < 0.001) were significantly shorter for this patient cohort. CPI therapy was well tolerated in both subcohorts with 15% discontinuing therapy due to toxicity. Our real-world data show that first-line CPI therapy produced strong and durable responses among patients with advanced cSCC. Immunocompromised patients were less likely to achieve long-term benefit from anti-PD1 treatment, despite similar tumor response rates.

AB - Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. Among 39 evaluable patients, the tumor response rate (rwTRR) was 48.6%, the median PFS was 29.0 months, and the median OS was not reached. In addition, 9 patients showed an impaired immune status due to immunosuppressive medication or hematological diseases. Our data demonstrated that CPI also evoked tumor responses among immunocompromised patients (rwTRR: 48.1 vs. 50.0%), although these responses less often resulted in durable remissions. In line with this, the median PFS (11 vs. 40 months, p = 0.059), TTNT (12 months vs. NR, p = 0.016), and OS (29 months vs. NR, p < 0.001) were significantly shorter for this patient cohort. CPI therapy was well tolerated in both subcohorts with 15% discontinuing therapy due to toxicity. Our real-world data show that first-line CPI therapy produced strong and durable responses among patients with advanced cSCC. Immunocompromised patients were less likely to achieve long-term benefit from anti-PD1 treatment, despite similar tumor response rates.

U2 - 10.3390/cancers14225543

DO - 10.3390/cancers14225543

M3 - SCORING: Journal article

C2 - 36428636

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 22

M1 - 5543

ER -